Why the study?
While oral anticoagulation is effective in patients with normal renal function, the impact of severe renal failure on patient outcomes and the potential benefit of a specialized coagulation service were unknown.
Does management in a specialized coagulation service improve clinical outcomes and reduce bleeding in patients requiring oral anticoagulation therapy, including those with severe renal failure, compared to usual medical care?
Does management in a specialized coagulation service improve clinical outcomes and reduce bleeding in patients requiring oral anticoagulation therapy, including those with severe renal failure, compared to usual medical care?
Management of oral anticoagulation therapy in a specialized coagulation service significantly reduces mortality, hospitalizations, and bleeding events compared to usual care, regardless of the patient's renal function.
These observational associations should not yet change anticoagulation practice; leaves open randomized trials of specialized coagulation services.
Oral anticoagulation (OAC) is effective at preventing and treating thromboses and thromboembolism in patients with normal renal function. We aimed to research the impact of severe renal failure (RF) on patient outcome and to determine the potential benefit of caring for these patients in a specialized coagulation service (CS). A total of 1516 usual medical care patients and 756 CS-managed patients of the thrombEVAL multicenter (21 centers), prospective, cohort study (NCT01809015) were analyzed in a 3-year follow-up. Patients with RF (serum creatinine >3 mg/dL, no renal replacement therapy) were compared to patients without RF in usual care and a CS. The fluctuations in the international normalized ratios were significantly lower in CS-managed patients, and regardless of treatment in usual care or a CS, the time in therapeutic range was significantly lower in RF patients. Cox regression-adjusted hazard ratios for long-term outcome (1.5, 95% CI: 1.22–1.83, p < 0.001), death (1.62, CI: 1.27–2.08, p < 0.001), and hospitalization (1.21, CI: 1.02–1.44, p = 0.032) were significantly higher in RF patients in usual care. Furthermore, there was a trend of more bleeding events in RF patients. CS-treated patients had significantly lower adjusted hazard ratios for death (0.24, CI: 0.14–0.39, p < 0.001), hospitalizations (0.41, CI: 0.34–0.5, p < 0.001), clinically relevant bleeding (0.29, CI: 0.18–0.47, p < 0.001), and major bleeding (0.33, CI: 0.18–0.59, p < 0.001). Thus, patients who required oral anticoagulation therapy benefitted significantly from being managed in a specialized coagulation service, regardless of their renal function.
No takes yet. Share an insight, caveat, or question.
Lauterbach et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: